Key result
Among patients with unexplained heart failure, the incidence of biopsy-documented myocarditis was 9.6%, with 111 patients randomized to immunosuppressive or conventional therapy.
Why the study?
Does immunosuppressive therapy improve LVEF in patients with biopsy-documented myocarditis and LVEF < 45%?
Population
111 patients with biopsy-documented myocarditis and LVEF < 45%, mean age 42.0 years.
Comparison
Immunosuppressive therapy plus conventional drug… vs Conventional therapy only for 24 weeks.
Design
RCT, Randomly assigned
Follow-up
52 weeks
Authors
Loading...
Establishes feasibility of biopsy-guided randomization in unexplained HF; leaves open whether immunosuppression improves LVEF.
RCT (n=111)
randomly assigned
Yes
Does immunosuppressive therapy improve LVEF in patients with biopsy-documented myocarditis and LVEF < 45%?
This paper describes the design and baseline characteristics of the Myocarditis Treatment Trial, which evaluates immunosuppressive therapy for biopsy-documented myocarditis.
Hahn et al. (1995) conducted an RCT in biopsy-documented myocarditis (n=111). immunosuppressive therapy plus conventional drug therapy vs. conventional therapy only was evaluated on mean increase in LVEF at week 28. Among patients with unexplained heart failure, the incidence of biopsy-documented myocarditis was 9.6%, with 111 patients randomized to immunosuppressive or conventional therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: